Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.

MLA

Pollyea, Daniel A., et al. “Venetoclax with Azacitidine or Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: Long Term Follow-up from a Phase 1b Study.” American Journal of Hematology, vol. 96, no. 2, Feb. 2021, pp. 208–17. EBSCOhost, https://doi.org/10.1002/ajh.26039.

APA

Pollyea, D. A., Pratz, K., Letai, A., Jonas, B. A., Wei, A. H., Pullarkat, V., Konopleva, M., Thirman, M. J., Arellano, M., Becker, P. S., Chyla, B., Hong, W.-J., Jiang, Q., Potluri, J., & DiNardo, C. D. (2021). Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American Journal of Hematology, 96(2), 208–217. https://doi.org/10.1002/ajh.26039

Chicago

Pollyea, Daniel A, Keith Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Vinod Pullarkat, Marina Konopleva, et al. 2021. “Venetoclax with Azacitidine or Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: Long Term Follow-up from a Phase 1b Study.” American Journal of Hematology 96 (2): 208–17. doi:10.1002/ajh.26039.